Home

ZOMETA in Advanced Cancers

For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.

ZOMETA in Advanced Cancers

This is an international site for Zometa^® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Zometa Information for US residents Zometa Information for Patients Outside the US

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in
95 countries
around the world.

ZOMETA Country-Level Websites

Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.

ZOMETA International Website

This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus .

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Text size:

Across a wide range of advanced cancers involving bone

ZOMETA helps reduce and delay SREs* that can threaten survival¹

ZOMETA helps reduce and delay SREs in patients with Advanced Cancers involving bone

ZOMETA is indicated for the prevention of SREs in patients with advanced malignancies involving bone.¹

*SRE=skeletal-related event—defined as pathological fracture, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcaemia.¹

Reference: 1. ZOMETA Summary of Product Characteristics. Novartis Pharma AG.

ZOMETA in Advanced Cancers

Welcome to the ZOMETA Product Website

ZOMETA is approved for use in 95 countries around the world.

ZOMETA Country-Level Websites

ZOMETA International Website

Across a wide range of advanced cancers involving bone

ZOMETA helps reduce and delay SREs* that can threaten survival1

ZOMETA is approved for use in
95 countries
around the world.

ZOMETA helps reduce and delay SREs* that can threaten survival¹